Efficacy and safety of larotrectinib as first-line treatment for patients with TRK fusion cancer.
- DOI
- 10.1016/j.esmoop.2025.105110
- Published
- 2025 Jun
- Container
- ESMO open
- Publisher
- Not recorded
- Open access
- yes
Credibility signals
limited evidence Score 45/100 under policy 1.0.0. This is a metadata assessment, not a judgment of the paper's conclusions.
Show all credibility signals
- cautionDOI registered: No matching Crossref record was present in this response.
- cautionDOI resolves: No matching Crossref record was present in this response.
- not scoredDirectory of Open Access Journals: No matching DOAJ record was present in this response. No allow-list match; this is not evidence of low credibility.
- not scoredMEDLINE indexed: Not checked or no result supplied; no credibility inference made.
- not scoredOpenAlex core source: Not checked or no result supplied; no credibility inference made.
- not scoredKnown publisher allow-list: Not checked or no result supplied; no credibility inference made.
- not scoredROR affiliation: Not checked or no result supplied; no credibility inference made.
- not scoredRetraction Watch retraction: No retraction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredRetraction Watch expression of concern: No expression of concern notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredRetraction Watch correction: No correction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredRetraction Watch reinstatement: No reinstatement notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- supportingOpen access status: Normalized open-access status: open.
- not scoredPublication license: Not checked or no result supplied; no credibility inference made.
- not scoredPublication version: A publication version was supplied but is not scored.
- cautionMetadata completeness: 5 of 6 scored descriptive metadata groups are present; missing fields increase uncertainty.
Cite this work
BibTeX
@article{allodium:10.1016/j.esmoop.2025.105110,
title = {Efficacy and safety of larotrectinib as first-line treatment for patients with TRK fusion cancer.},
author = {Hong DS and Xu RH and Shen L and Dierselhuis MP and Orbach D and McDermott R and Italiano A and Tahara M and Bernard-Gauthier V and Neu N and Mussi CE and De La Cuesta E and Laetsch TW and Drilon A},
year = {2025},
journal = {ESMO open},
doi = {10.1016/j.esmoop.2025.105110},
url = {https://doi.org/10.1016/j.esmoop.2025.105110}
}RIS
TY - JOUR TI - Efficacy and safety of larotrectinib as first-line treatment for patients with TRK fusion cancer. AU - Hong DS AU - Xu RH AU - Shen L AU - Dierselhuis MP AU - Orbach D AU - McDermott R AU - Italiano A AU - Tahara M AU - Bernard-Gauthier V AU - Neu N AU - Mussi CE AU - De La Cuesta E AU - Laetsch TW AU - Drilon A PY - 2025 JO - ESMO open DO - 10.1016/j.esmoop.2025.105110 UR - https://doi.org/10.1016/j.esmoop.2025.105110 ER -
APA
DS, H., RH, X., L, S., MP, D., D, O., R, M., A, I., M, T., V, B., N, N., CE, M., E, D. L. C., TW, L., & A, D. (2025). Efficacy and safety of larotrectinib as first-line treatment for patients with TRK fusion cancer.. ESMO open. https://doi.org/10.1016/j.esmoop.2025.105110
Source records
- pubmed · retrieved 2026-09-26T10:10:13.290Z